60PResponse rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials. (17th December 2018) - Gogas, H; Gutzmer, R; Malvehy, J; Mehnert, J M; Liu, K; Pickett, C A; Snyder, W; Chesney, J